Metformin suppresses pancreatic tumor growth with inhibition of NFκB/STAT3 inflammatory signaling

Pancreas

Volumn 44, Issue 4, 2015, Pages 636-647

  Tan, Xiang Lin ^a,b,c   Bhattacharyya, Kalyan K ^d   Dutta, Shamit K ^d   Bamlet, William R ^a   Rabe, Kari G ^a   Wang, Enfeng ^d   Smyrk, Thomas C ^a   Oberg, Ann L ^a   Petersen, Gloria M ^a   Mukhopadhyay, Debabrata ^d  

^a MAYO CLINIC   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c RUTGERS SCHOOL OF PUBLIC HEALTH   (United States)

^d MAYO GRADUATE SCHOOL   (United States)

Author keywords

chemoprevention; inflammation; metformin; pancreatic cancer

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; K RAS PROTEIN; MESSENGER RNA; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN P53; STAT3 PROTEIN; THROMBOSPONDIN 1; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; TRANSCRIPTION FACTOR SP4; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A; ANTINEOPLASTIC AGENT; STAT3 PROTEIN, MOUSE; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENETICALLY ENGINEERED MOUSE STRAIN; HETEROZYGOSITY; HOMOZYGOSITY; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MALE; MOUSE; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG ADMINISTRATION; DRUG EFFECTS; EVALUATION STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; POLYMERASE CHAIN REACTION; RANDOMIZATION; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; DRUG ADMINISTRATION SCHEDULE; FEMALE; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAPERITONEAL; MALE; METFORMIN; MICE; MICE, TRANSGENIC; NF-KAPPA B; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR BURDEN;

EID: 84928489682     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000308     Document Type: Article

References (67)

1. Bodmer M, Meier C, Krahenbuhl S, et al. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 2010;33: 1304-1308.
2. Li D, Yeung SC, Hassan MM, et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009;137:482-488.
3. Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control. 2009;20:1617-1622.
4. Hosono K, Endo H, Takahashi H, et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila). 2010;3:1077-1083.
5. Bodmer M, Becker C, Meier C, et al. Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol. 2012; 107:620-626.
6. Lee MS, Hsu CC, Wahlqvist ML, et al. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer. 2011;11:20.
7. Bosco JL, Antonsen S, Sorensen HT, et al. Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev. 2011;20:101-111.
8. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, et al. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther. 2010;9:1092-1099.
9. Schneider MB, Matsuzaki H, Haorah J, et al. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology. 2001;120: 1263-1270.
10. Kisfalvi K, Eibl G, Sinnett-Smith J, et al. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res. 2009;69:6539-6545.
11. Memmott RM, Mercado JR, Maier CR, et al. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res (Phila). 2010;3: 1066-1076.
12. Algire C, Zakikhani M, Blouin MJ, et al. Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer. 2008;15:833-839.
13. Hosono K, Endo H, Takahashi H, et al. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinog. 2010;49:662-671.
14. Bhalla K, Hwang BJ, Dewi RE, et al. Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res (Phila). 2012;5:544-552.
15. Rattan R, Ali Fehmi R, Munkarah A. Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis. J Oncol. 2012;2012:928127.
16. Algire C, Amrein L, Bazile M, et al. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene. 2011;30:1174-1182.
17. Sadeghi N, Abbruzzese JL, Yeung SC, et al. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res. 2012;18:2905-2912.
18. Kisfalvi K,Moro A, Sinnett-Smith J, et al. Metformin inhibits the growth of human pancreatic cancer xenografts. Pancreas. 2013;42:781-785.
19. Nair V, Pathi S, Jutooru I, et al. Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors. Carcinogenesis. 2013;34:2870-2879.
20. Mohammed A, Janakiram NB, Brewer M, et al. Antidiabetic drug metformin prevents progression of pancreatic cancer by targeting in part cancer stem cells and mTOR signaling. Transl Oncol. 2013;6:649-659.
21. Ren YX, Xu GM, Li ZS, et al. Detection of point mutation in K-ras oncogene at codon 12 in pancreatic diseases. World J Gastroenterol. 2004; 10:881-884.
22. Eckel F, Schneider G, Schmid RM. Pancreatic cancer: a review of recent advances. Expert Opin Investig Drugs. 2006;15:1395-1410.
23. Mohammed A, Janakiram NB, Lightfoot S, et al. Early detection and prevention of pancreatic cancer: use of genetically engineered mouse models and advanced imaging technologies. Curr Med Chem. 2012;19: 3701-3713.
24. Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7:469-483.
25. Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4: 437-450.
26. Jonkers J, Meuwissen R, van der Gulden H, et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet. 2001;29:418-425.
27. Chin L, Tam A, Pomerantz J, et al. Essential role for oncogenic Ras in tumour maintenance. Nature. 1999;400:468-472.
28. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22:659-661.
29. Olivier M, Eeles R, Hollstein M, et al. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat. 2002; 19:607-614.
30. Viollet B, Guigas B, Sanz Garcia N, et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012;122: 253-270.
31. Hattori Y, Suzuki K, Hattori S, et al. Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension. 2006;47:1183-1188.
32. Yang J, Stark GR. Roles of unphosphorylated STATs in signaling. Cell Res. 2008;18:443-451.
33. Abdelrahim M, Baker CH, Abbruzzese JL, et al. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst. 2006;98:855-868.
34. Abdelrahim M, Baker CH, Abbruzzese JL, et al. Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res. 2007;67:3286-3294.
35. Jutooru I, Chadalapaka G, Lei P, et al. Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation. J BiolChem. 2010;285:25332-25344.
36. Jiang NY,Woda BA, Banner BF, et al. Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2008;17:1648-1652.
37. Jiang Q, Liu P, Wu X, et al. Berberine attenuates lipopolysaccharide-induced extracelluar matrix accumulation and inflammation in rat mesangial cells: involvement of NF-kappaB signaling pathway. Mol Cell Endocrinol. 2011;331:34-40.
38. Riad A, Du J, Stiehl S, et al. Low-dose treatment with atorvastatin leads to anti-oxidative and anti-inflammatory effects in diabetes mellitus. Eur J Pharmacol. 2007;569:204-211.
39. Soetikno V, Sari FR, Veeraveedu PT, et al. Curcumin ameliorates macrophage infiltration by inhibiting NF-κB activation and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy. Nutr Metab (Lond). 2011;8:35.
40. Chow FY, Nikolic-Paterson DJ, Ma FY, et al. Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Diabetologia. 2007;50:471-480.
41. Mezzano S, Aros C, Droguett A, et al. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant. 2004;19:2505-2512.
42. Yun H, Lee M, Kim SS, et al. Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma. J BiolChem. 2005;280:9963-9972.
43. Neurath KM, Keough MP, Mikkelsen T, et al. AMP-dependent protein kinase alpha 2 isoform promotes hypoxia-induced VEGF expression in human glioblastoma. Glia. 2006;53:733-743.
44. Nagata D, Mogi M, Walsh K. AMP-activated protein kinase (AMPK) signaling in endothelial cells is essential for angiogenesis in response to hypoxic stress. J Biol Chem. 2003;278:31000-31006.
45. Ouchi N, Shibata R, Walsh K. AMP-activated protein kinase signaling stimulates VEGFexpression and angiogenesis in skeletal muscle. Circ Res. 2005;96:838-846.
46. Zhang X, Lawler J. Thrombospondin-based antiangiogenic therapy. Microvasc Res. 2007;74:90-99.
47. McMahon GA, Petitclerc E, Stefansson S, et al. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem. 2001; 276:33964-33968.
48. YueW, Yang CS, DiPaola RS, et al. Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. Cancer Prev Res (Phila). 2014;7:388-397.
49. Erkan M, Reiser-Erkan C, Michalski CW, et al. Tumor microenvironment and progression of pancreatic cancer. Exp Oncol. 2010;32:128-131.
50. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007;117:1175-1183.
51. Aggarwal BB, Sethi G, Ahn KS, et al. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci. 2006;1091:151-169.
52. Niu J, Li Z, Peng B, et al. Identification of an autoregulatory feedback pathway involving interleukin-1alpha in induction of constitutive NF-kappaB activation in pancreatic cancer cells. J Biol Chem. 2004;279: 16452-16462.
53. Scholz A, Heinze S, Detjen KM, et al. Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology. 2003;125:891-905.
54. Toyonaga T, Nakano K, Nagano M, et al. Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer. Cancer Lett. 2003; 201:107-116.
55. Fujioka S, Sclabas GM, Schmidt C, et al. Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis. Oncogene. 2003;22:1365-1370.
56. Salminen A, Hyttinen JM, Kaarniranta K. AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan. J Mol Med (Berl). 2011;89:667-676.
57. Morin-Papunen L, Rautio K, Ruokonen A, et al. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:4649-4654.
58. Takemura Y, Osuga Y, Yoshino O, et al. Metformin suppresses interleukin (IL)-1beta-induced IL-8 production, aromatase activation, and proliferation of endometriotic stromal cells. J Clin EndocrinolMetab. 2007;92: 3213-3218.
59. Huang NL, Chiang SH, Hsueh CH, et al. Metformin inhibits TNF-alpha-induced IkappaB kinase phosphorylation, IkappaB-alpha degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation. Int J Cardiol. 2009;134: 169-175.
60. Kim HG, Hien TT, Han EH, et al. Metformin inhibits P-glycoprotein expression via the NF-kappaB pathway and CRE transcriptional activity through AMPK activation. Br J Pharmacol. 2011;162: 1096-1108.
61. Isoda K, Young JL, Zirlik A, et al. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol. 2006;26:611-617.
62. Xavier DO, Amaral LS, Gomes MA, et al. Metformin inhibits inflammatory angiogenesis in a murine sponge model. Biomed Pharmacother. 2010;64:220-225.
63. Baba T, Shimada K, Neugebauer S, et al. The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients. Diabetes Care. 2001;24:953-954.
64. Deng XS, Wang S, Deng A, et al. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle. 2012;11:367-376.
65. Sclabas GM, Uwagawa T, Schmidt C, et al. Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin. Cancer. 2005;103:2485-2490.
66. Zhang Z, Rigas B. NF-kappaB, inflammation and pancreatic carcinogenesis: NF-kappaB as a chemoprevention target (review). Int J Oncol. 2006;29:185-192.
67. Rao CV, Mohammed A, Janakiram NB, et al. Inhibition of pancreatic intraepithelial neoplasia progression to carcinoma by nitric oxide-releasing aspirin in p48(Cre/+)-LSL-Kras(G12D/+) mice. Neoplasia. 2012;14:778-787.